PT-141 Lab Monitoring: What to Watch | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

PT-141 (Bremelanotide) lab monitoring

Lab guideLast updated: October 28, 2026

What to monitor when using PT-141 (bremelanotide), and why routine blood work isn't part of it. PT-141 is the FDA-approved drug Vyleesi, for low sexual desire (HSDD) in premenopausal women, so unlike most peptides on this site it has phase 3 trial data and an FDA label (PMID 31599840). That label calls for no lab tests. What it does flag is blood pressure, who shouldn't use it, how often it can be taken, and skin darkening.

Read this firstThe Vyleesi label says it is contraindicated with "uncontrolled hypertension or known cardiovascular disease". Each dose raises blood pressure for several hours. Heart disease, or high blood pressure that isn't well controlled? Don't use it.

No routine labs

No routine blood work is required for PT-141. It's taken as needed before sexual activity, not dosed daily over a cycle, and the FDA label for Vyleesi recommends no laboratory monitoring. Its known risks (blood pressure, nausea, skin darkening) don't show up in blood tests.

Safety monitoring

  • Blood pressure: what to expect

    Vyleesi "transiently increases blood pressure and reduces heart rate after each dose": up to 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after the dose, with heart rate down by up to 5 beats per minute. Both "returned to baseline usually within 12 hours post-dose" (Vyleesi label). In an ambulatory study, the 1.75 mg dose raised systolic pressure by about 3 mmHg over the first 4 hours (PMID 27977473).

  • Blood pressure: when to check

    The label says that before starting, and periodically during treatment, the prescriber should "consider the patient's cardiovascular risk and ensure blood pressure is well-controlled." In practice: know your resting blood pressure before the first dose, especially if you take blood-pressure medication. Recheck 2 to 4 hours after your first few doses, when the rise peaks.

  • Blood pressure: when to stop

    Normal is under 120/80. Stage 2 hypertension starts at 140 systolic or 90 diastolic (CDC, using ACC/AHA categories). A reading in the stage 2 range, or chest pain, a severe headache or palpitations after a dose, is a reason to stop and see a clinician.

What to watch for

  • Skin darkening (focal hyperpigmentation)

    Dark patches on the face, gums or breasts were reported in 1% of trial patients taking up to 8 doses a month. In a separate study, 38% developed them after 8 daily doses in a row. People with darker skin were more likely to get them, and they didn't always fade after stopping (Vyleesi label).

  • Nausea

    The most common side effect: 40% of patients in the phase 3 trials, with 13% needing anti-nausea medication and 8% stopping because of it (Vyleesi label). Flushing (about 20%) and headache (about 12%) were also common in the long-term extension (PMID 31599847).

  • Oral naltrexone

    Avoid using PT-141 with oral naltrexone taken for alcohol or opioid dependence. Vyleesi "may significantly decrease the systemic exposure of orally-administered naltrexone", and naltrexone failing in that setting can have severe consequences (Vyleesi label).

Contraindications

  • Uncontrolled hypertension (Vyleesi label).
  • Known cardiovascular disease (Vyleesi label).
  • Not recommended for people at high risk of cardiovascular disease (Vyleesi label).

Dosing limits

  • No more than 1 dose in 24 hours

    The label says patients "should not administer more than one dose within 24 hours"; doses close together may add up their effect on blood pressure.

  • No more than 8 doses a month

    More than 8 a month is not recommended. More frequent dosing raises the chance of skin darkening and lengthens the time each month that blood pressure is raised (Vyleesi label).

  • Label dose

    1.75 mg under the skin, at least 45 minutes before sexual activity (Vyleesi label). The commonly reported community doses of 0.5-2 mg straddle that, but grey-market vials are not the approved autoinjector.

Rare events and case reports

  • One case of acute hepatitis

    In the open-label extension of one trial, one patient who had taken 10 doses over a year developed acute hepatitis, with liver enzymes over 40 times the upper limit of normal. Her liver tests returned to normal 4 months after stopping. No other cause was found, so the drug's role "could not definitively be excluded", but there was no imbalance in liver-test outliers across the trial program (Vyleesi label). If you develop abdominal pain, yellowing skin or eyes, dark urine or unusual tiredness while using it, stop and ask a clinician for liver tests (ALT, AST).

Optional labs (not routine for PT-141 (Bremelanotide))

Vyleesi is "not indicated for the treatment of HSDD in postmenopausal women or in men" (label), and no PT-141 trial in men has measured testosterone. These tests aren't for monitoring PT-141. For a man using it off-label for sexual function, they can check for an underlying cause such as low testosterone before relying on a drug.

MarkerWhy test itStandard range
Total testosterone
Testosterone, total (morning draw)
The starting point for evaluating suspected testosterone deficiency, alongside symptoms (AUA guideline, PMID 29601923). Draw in the morning.Adult men: 264-916 ng/dL
Source: Labcorp test 004226
Free testosterone
Testosterone, free
Often added when total testosterone is borderline. Read it against your lab's own range.See your lab report
SHBG
Sex hormone-binding globulin
Affects how much testosterone is free; often ordered with total testosterone.See your lab report
Estradiol
Estradiol
Sometimes added as part of a male hormone workup. Read it against your lab's own range.See your lab report

Your labs can't check your vial

The approved product is Vyleesi, a 1.75 mg prefilled autoinjector. Grey-market PT-141 is a different product: no peer-reviewed study has tested it for identity or purity, and FDA has not named bremelanotide in its compounding safety review. No blood test can tell you what's in a vial. Identity and purity get checked on the product's certificate of analysis, against the testing lab's own record.

Verify a lab certificate on ThirdPartyVerified →

What the research doesn't show

  • The approval data is in premenopausal women: two 24-week phase 3 trials of 1,267 women (PMID 31599840) and a 52-week open-label extension (PMID 31599847).
  • Men's trials (erectile dysfunction) are older and smaller, and used other doses and routes, including a nasal spray (PMID 14963471). None reported testosterone results.
  • The 38% skin-darkening figure came from 8 daily doses in a row, beyond the label's limits. At up to 8 doses a month it was 1% (Vyleesi label).

Sources

  1. FDA: VYLEESI (bremelanotide injection) prescribing information, revised October 2026 (S-005)
  2. Kingsberg SA, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol 2019. PMID 31599840
  3. Simon JA, et al. Long-term safety and efficacy of bremelanotide for hypoactive sexual desire disorder. Obstet Gynecol 2019. PMID 31599847
  4. White WB, et al. Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide. J Hypertens 2017. PMID 27977473
  5. Diamond LE, et al. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res 2004. PMID 14963471
  6. Mulhall JP, et al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol 2018. PMID 29601923
  7. CDC: About high blood pressure (blood pressure categories, from ACC/AHA)
  8. Labcorp test 004226: Testosterone, total (reference range)
  9. FDA: Certain bulk drug substances for use in compounding that may present significant safety risks (bremelanotide not named)

Educational content, not medical advice. If you're considering PT-141, talk to a clinician, especially if you have heart disease, high blood pressure or take other medications.